Galectin Therapeutics
GALT
51 hedge funds and large institutions have $7.02M invested in Galectin Therapeutics in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 9 closing their positions.
12% less funds holding
Funds holding: 58 → 51 (-7)
23% less capital invested
Capital invested by funds: $9.08M → $7.02M (-$2.06M)
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
67% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 9
95% less call options, than puts
Call options by funds: $4K | Put options by funds: $85K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$404K |
| 2 |
AIG
American International Group
New York
|
+$104K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$36.3K |
| 4 |
Creative Planning
Overland Park,
Kansas
|
+$18.4K |
| 5 |
Millennium Management
New York
|
+$14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$560K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$434K |
| 3 |
D.E. Shaw & Co
New York
|
-$384K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$278K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$124K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCIM
51
TIAA CREF Investment Management
New York
| – | -$57K | -20,798 | Closed |
|
|
AGM
52
Alpine Global Management
New York
| – | -$37K | -13,681 | Closed |
|
|
PPA
53
Parametric Portfolio Associates
Seattle,
Washington
| – | -$32K | -11,613 | Closed |
|
|
LP
54
LMR Partners
London,
United Kingdom
| – | -$27K | -10,099 | Closed |
|
55
Simplex Trading
Chicago,
Illinois
| – | +$118 | +50 | New |
|
|
AAM
56
American Asset Management
Boca Raton,
Florida
| – | +$198 | +84 | New |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$366 | +155 | +58% |
|
GALT Hedge Fund Activity: Q3 2015 in Review
51 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q3 2015, worth a combined $7.02M — down 23% from $9.08M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of GALT and 3 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 10 added.
The largest buyer was D.A. Davidson & Co, adding an estimated $404K. The largest seller was Sphera Funds Management, exiting entirely with an estimated $560K sold.
- 51 institutional investors held Galectin Therapeutics (GALT) as of Q3 2015, down from 58 in Q2 2015.
- Funds reported $7.02M of Galectin Therapeutics stock for Q3 2015, down 23% quarter-over-quarter.
- 3 funds opened new Galectin Therapeutics positions in Q3 2015 and 9 closed out, a net change of -6 holders.
- The largest Galectin Therapeutics buyer in Q3 2015 was D.A. Davidson & Co, an estimated $404K added.
- The largest Galectin Therapeutics seller in Q3 2015 was Sphera Funds Management, an estimated $560K sold.
Based on aggregated 13F filings for Q3 2015.